News


March 4, 2017


Phase I/II data presented at 2017 late-breaking research at American Academy of Dermatology

Short Hills, NJ, March 4, 2017– Tamir Biotechnology, a leading developer of antiviral therapies, presented data demonstrating the safety and efficacy of topical ranpirnase in the treatment of HPV associated genital warts during the 2017 American Academy of Dermatology late-breaking research session. The company’s leading asset, topical ranpirnase, was evaluated in a formal phase I/II, double blinded investigation in seventy-five (75) immunocompetent subjects with genital warts. Patients received either topical ranpirnase or vehicle (control), with twice a day application to the affected area for a period of eight (8) weeks. The dose of ranpirnase was 1mg/week.

(more…)

Continue reading

July 28, 2016


San Diego, CA — Tamir Biotechnology, a leading developer of antiviral therapies, announced today the publication in the peer reviewed journal Antiviral Research, of ranpirnase activity against the Ebola virus. In this study involving both laboratory (in-vitro) and an established animal (in-vivo) model of Ebola infection, the authors confirmed the ability of ranpirnase to inhibit viral replication of Ebola, reduce virus levels of Ebola of infected mice and significantly extend survival times of animals treated with ranpirnase compared to a control animal group.

(more…)

Continue reading

February 23, 2016


SAN DIEGO, Feb. 22, 2016 /PRNewswire/ — Tamir Biotechnology, a clinical stage company developing ranpirnase as a novel broad-spectrum anti-viral, announced results today from a pre-clinical investigational study at the Institute of Antiviral Research at Utah State University.

Read the full article here.
From prnewswire.com

Continue reading

May 11, 2015


SAN DIEGO, April 30, 2015 /PRNewswire/ — Tamir Biotechnology, a leading developer of RNA modulating drugs, announced today an update on its Ebola antiviral therapy program.

Read the full article here.
From prnewswire.com

Continue reading

April 10, 2015


MedicalResearch.com Interview with:
Luis Squiquera, MD
Tamir Biotechnology

MedicalResearch: What is the background for this study? What are the main findings?

Dr. Squiquera: Ranpirnase is a small peptide that has a characteristic enzymatic activity against double stranded RNA (dsRNA). As a drug it has been extensively tested intravenously in high concentration for oncology in over 1000 patients with different types of malignancy, especially mesothelioma, with minimal side effects and mainly a transient increase of serum creatinine level observed.

Read the full article here.
From medicalresearch.com

Continue reading

April 3, 2015


SAN FRANCISCO — The experimental antiviral drug ranpirnase can completely clear away the warts caused by human papillomavirus (HPV), a preliminary study has shown.

If these results are borne out in further studies, ranpirnase would be the first drug to attakc HPV itself, said Eric Daniels, MD, a research consultant for Tamir Biotechnology in San Diego.

Read the full article here. (PDF)
From www.medscape.com

Continue reading

April 1, 2015


SAN FRANCISCO — Three-fourths of men with anogenital warts caused by human papillomavirus (HPV) had clinical remission and the rest had partial responses to a frog-derived enzyme, investigators reported here.

Clinical remission occurred in 18 of 24 evaluable patients in response to ranpirnase, an endoribonuclease derived from the eggs of Rana pipiens, or Northern Leopard frog. The patients received 1 mg/mL BID of a topical formulation of ranpirnase, and remissions occurred, on average, within 33 days of starting treatment, Luis Squiquera, MD, of Tamir Biotechnology, reported at the American Academy of Dermatology meeting.

Read the full article here.
From www.medpagetoday.com

Continue reading
Back to top